Yaden Laboratories Becomes the First Sri Lankan Pharma Manufacturer to Exhibit at CPHI Europe in Milan

AI-generated illustration. No photograph from Yaden Laboratories or the CPHI Europe exhibition is embedded.

Yaden Laboratories has marked a notable milestone for Sri Lankan manufacturing by becoming the first pharmaceutical manufacturer from the country to exhibit at CPHI Europe 2026, held in Milan, Italy, from 6 to 8 October. The achievement, reported by the Daily FT on 13 October, placed a Sri Lankan producer among international businesses presenting their capabilities at one of the pharmaceutical industry’s major global gatherings.

For Sri Lanka, the significance extends beyond a company’s presence at an overseas exhibition. CPHI brings together manufacturers, suppliers and buyers from across the pharmaceutical supply chain, providing a forum in which businesses can introduce their expertise, explore industry connections and learn about developments in international markets. Yaden’s participation offers a visible indication of the capabilities being developed within Sri Lanka’s own pharmaceutical manufacturing sector.

The exhibition itself should not be mistaken for proof of new commercial agreements or contracts. Rather, the milestone is the opportunity for a local manufacturer to be represented at a global industry platform, where international engagement can help raise the profile of Sri Lankan production and contribute to longer-term export ambitions.

A Sri Lankan manufacturer specialising in sterile medicines

Yaden Laboratories is based in the Katunayake Export Processing Zone and specialises in sterile injectable formulations. The company’s website describes its product focus as including injectable medicines, pre-filled syringes, and eye and ear drops. It also notes that the business was founded in 2012 as Yaden International, initially addressing medical supply needs through the import and marketing of pharmaceutical products before developing its manufacturing operations.

Sterile injectables are medicines administered by injection and must be manufactured to stringent standards. Unlike tablets taken by mouth, these products are introduced directly into the body, making sterility, consistent production and careful quality controls essential. Their manufacture depends on controlled environments, validated processes, trained personnel and thorough testing, alongside compliance with relevant regulatory requirements.

These demands make sterile injectable production a technically complex area of pharmaceutical manufacturing. The ability to produce such medicines locally is therefore a meaningful sign of industrial capability: it requires more than manufacturing equipment alone, depending also on quality systems, specialised knowledge and sustained investment.

AI-generated illustration of quality inspection in a pharmaceutical cleanroom; it does not depict Yaden Laboratories’ actual facility.

The Sri Lanka Pharmaceutical Manufacturers Association (SLPMA) has previously reported that Yaden became the first Sri Lankan company to export locally made sterile liquid injectables. Its 2025 account described the company’s first export consignment to Zambia, consisting of medicines including ketamine and midazolam injections, and noted the company’s intention to expand beyond the domestic market. That export record provides important context for the CPHI milestone: Yaden’s international presence is part of a wider effort to establish Sri Lankan-made sterile formulations in overseas markets.

Why international visibility matters

A place at a major trade exhibition can help manufacturers present their products and production capabilities to an international audience. For a Sri Lankan company, participation also creates an opportunity to demonstrate that pharmaceutical manufacturing is not limited to established industrial economies. It signals that local companies are seeking a place in a sector where production standards, reliability and regulatory compliance are central to building trust.

Such visibility may support future discussions with industry participants, but the outcomes of an exhibition depend on many factors and develop over time. No commercial agreements or sales resulting from Yaden’s attendance have been reported in the sources cited here. The significance lies in the company’s representation and in the broader recognition of Sri Lanka’s capacity to manufacture specialised pharmaceutical products.

AI-generated illustration symbolising pharmaceutical export potential; the packages and logistics scene are not a depiction of Yaden’s products or shipments.

There is also a wider public interest in building local pharmaceutical production. Where quality medicines can be produced in Sri Lanka to the required standards, domestic manufacturing can contribute to a more diverse supply base and strengthen the country’s ability to meet some health-sector needs from local sources. This does not mean that local production can replace imports across the full range of medicines, nor does it guarantee uninterrupted supply; it does, however, underline the value of developing specialised capacity at home.

For a country whose pharmaceutical sector has relied substantially on imported medicines, strengthening local manufacturing can be an important part of longer-term medicine security. Export development can support that effort by helping local manufacturers reach markets beyond Sri Lanka, broaden their experience and build the scale needed to sustain specialised production. The path is demanding, requiring quality assurance, regulatory alignment and dependable operations, but Yaden’s history of exporting sterile injectables demonstrates a practical step in that direction.

AI-generated illustration of sterile injectable inspection; it is not a photograph of Yaden Laboratories.

A milestone for Sri Lankan industry

For Sri Lankans at home and abroad, Yaden Laboratories’ CPHI Europe appearance is a positive development to follow because it reflects a growing ambition to participate in high-value manufacturing and international trade. The story is relevant not only to the pharmaceutical sector, but also to the broader discussion about how Sri Lankan businesses can develop expertise, create export opportunities and present their capabilities in global markets.

The achievement is best understood as a milestone rather than an endpoint. A strong international presence is built through consistent product quality, regulatory compliance and reliable supply, supported by investment in people and modern manufacturing systems. Yaden’s exhibit in Milan placed a Sri Lankan pharmaceutical manufacturer on an important international stage; its previous sterile-injectable export record shows that this presence is accompanied by experience in overseas supply.

AI-generated illustration. No photograph from Yaden Laboratories or the CPHI Europe exhibition is embedded.

As the country considers the future of its industrial and export sectors, the development of specialised pharmaceutical manufacturing offers a clear example of local capability with international relevance. Yaden Laboratories’ participation at CPHI Europe 2026 is an encouraging step for the company and a noteworthy moment for Sri Lanka’s ambition to make, and export, more of the medicines needed by patients.

Sources:

• Daily FT: https://www.ft.lk/front-page/Yaden-Laboratories-makes-history-as-first-Sri-Lankan-pharmaceutical-manufacturer-to-exhibit-at-CPHI-Europe-2026/44-798598
• Yaden Laboratories, About Us: https://yadenlabs.com/about-us/
• Sri Lanka Pharmaceutical Manufacturers Association: https://www.slpma.lk/yaden-laboratories-first-to-export-sri-lankan-made-sterile-liquid-injectables/

This article was written based on the source https://www.ft.lk/front-page/Yaden-Laboratories-makes-history-as-first-Sri-Lankan-pharmaceutical-manufacturer-to-exhibit-at-CPHI-Europe-2026/44-798598, with background from https://yadenlabs.com/about-us/ and https://www.slpma.lk/yaden-laboratories-first-to-export-sri-lankan-made-sterile-liquid-injectables/. Kindly email us at info@eLanka.com.au if any information needs to be corrected.

eLanka Disclaimer

Content published on eLanka may be created by the eLanka team, submitted by contributors or third parties, reproduced or adapted from other sources with appropriate source acknowledgement, or provided as promotional/advertising material by our clients. While eLanka takes reasonable care in preparing and publishing content, we do not warrant its completeness or accuracy. Views expressed are those of the respective authors or contributors and do not necessarily represent the views of eLanka. Third-party contributors, content providers and advertisers are responsible for the accuracy of material they supply and for ensuring they hold the necessary rights and permissions for its publication. Advertising and promotional content should not be regarded as an endorsement by eLanka of any product, service or claim.